Cancer: A Journal of the American Cancer SocietyPrintz (2. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continu ous hormone therapy, authors say[J]. Cancer, 2013, 119 (17) 3103 3104....
Hormone-refractory prostate cancer (HRPC) encompasses a wide spectrum of patients, including patients with prostate-specific antigen (PSA)–only disease, those with increasing PSA levels yet stable metastatic disease, and those with increasing PSA levels and objective evidence of progressive metastases. ...
Less than 2% of women are taking hormone therapy for menopause symptoms, likely due to a past study that raised safety concerns.Sept 17, 2024 embed code copied Live Now CBS News 24/7 CBS News Baltimore CBS News Bay Area CBS News Boston CBS News Chicago CBS News Colorado CBS ...
How Should We Treat Patients with Locally Advanced Prostate Cancer? Men with locally advanced prostate cancer are generally offered active treatment (radiotherapy or hormone therapy alone or in combination) with the aim of ... M Mason - 《European Urology Supplements》 被引量: 10发表: 2003年 Ho...
Orgovyx is the first oral drug to treat patients with advanced prostate cancer, who were previously treated with intravenous drugs that required clinic visits. The first oral hormone therapy to treat advanced prostate cancer, Orgovyx (relugolix), has been approved by the Food and Drug ...
PATIENTS AND METHODS—PATCH is a multicentre, randomized, phase II trial for men with locally advanced or metastatic prostate cancer, comparing luteinizing hormone-releasing hormone agonist therapy...doi:10.1016/j.maturitas.2015.02.320Langley, Ruth E....
Veru Inc. today announced positive top line data interim results from its Phase 2 clinical study of Zuclomiphene citrate, a nonsteroidal oral estrogen receptor agonist, for the treatment of androgen deprivation hormone therapy (ADT) induced hot flashes,
Advances in the treatment of breast cancer, adjuvant therapy, and neoadjuvant therapy [1:27:00]; The use of hormone replacement therapy in women who are in remission from breast cancer [1:41:15]; The role of genetics in breast cancer [1:44:45]; The importance of multidisciplinary care de...
Logistic Regression of Variables Associated With Receipt of Concurrent Therapy With Sipuleucel-T (n = 67) 1. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422. do...
Waeckerle-Men et al., Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma, Cancer Immunol Immunother 55: 1524-1533, 2006. Machlenkin et al., Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development...